Production (Stage)
China Pharma Holdings, Inc.
CPHI
$2.22
$0.010.45%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -35.41% | -28.76% | -21.36% | -24.11% | -13.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -35.41% | -28.76% | -21.36% | -24.11% | -13.48% |
| Cost of Revenue | -10.67% | -6.21% | -1.79% | -16.70% | -15.18% |
| Gross Profit | -606.12% | -1,095.35% | -2,431.77% | -410.98% | 43.08% |
| SG&A Expenses | 3.97% | -8.73% | -11.49% | -16.85% | -22.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.61% | -3.77% | -1.90% | -15.69% | -16.22% |
| Operating Income | -66.76% | -67.28% | -55.10% | -7.76% | 22.46% |
| Income Before Tax | -53.84% | -52.50% | -40.97% | -4.07% | 22.50% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -53.84% | -52.50% | -40.97% | -4.07% | 22.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -53.84% | -52.50% | -40.97% | -4.07% | 22.50% |
| EBIT | -66.76% | -67.28% | -55.10% | -7.76% | 22.46% |
| EBITDA | -109,594.44% | -15,182.14% | -4,002.12% | -25.82% | 100.21% |
| EPS Basic | 74.78% | 79.40% | 74.13% | 70.26% | 70.63% |
| Normalized Basic EPS | 74.78% | 79.40% | 74.13% | 70.26% | 70.63% |
| EPS Diluted | 74.78% | 79.40% | 74.13% | 70.26% | 70.63% |
| Normalized Diluted EPS | 74.78% | 79.40% | 74.13% | 70.26% | 70.63% |
| Average Basic Shares Outstanding | 426.38% | 644.09% | 600.47% | 407.80% | 214.62% |
| Average Diluted Shares Outstanding | 426.38% | 644.09% | 600.47% | 407.80% | 214.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |